The randomized, controlled FLOW-AF clinical trial represented the first attempt to determine if EGF mapping could be employed in a clinical setting to provide prognostic information and guide the targeted ablation of AF sources in difficult-to-treat redo and PeAF patients. This evidence concerns the gene EGF and atrial fibrillation.